Ravuconazole (codenamed BMS-207147 and ER-30346) is a potent triazole antifungal, being developed by Bristol-Myers Squibb, that is currently in phase I/II clinical trials. The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life. However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.

CAS：182760-06-1
中文别名：里氟康唑;4-[2-[(2R,3r)-3-(2,4-二氟苯基)-3-羟基-4-(1,2,4-噻唑)丁基]-1,3-噻唑]苯甲腈;
英文别名：RCZ;4-[2-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile;
分子式：C22H17F2N5OS
分子量：437.465
精确质量：437.112
Psa：115.86
Logp：4.24298

UNII：95YH599JWV

密度：1.38g/cm3
沸点：674.9ºC at 760 mmHg
闪点：362ºC
折射率：1.665
蒸汽压：3.89E-19mmHg at 25°C

危险性防范说明：P280; P305 + P351 + P338; P337 + P313
信号词：Warning
危险标志：GHS07
危险性描述：H315; H319; H335